1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 (Suppl. 1A): 5S–13S.
2. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol 2002; 168: 1720–2.
3. Gales AC, Jones RN, Gordon KA et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother 2000; 45: 295–303.
4. Ruden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the First National Prevalence Study (NIDEP). Infection 1997; 25: 199–202.
5. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. Emerg Infect Dis 2001; 7: 342–7.
6. Patton JP, Nash DB, Abrutyn E. Urinary tract infection: economic considerations. Med Clin North Am 1991; 75: 495–513.
7. Kass EH. Bacteriuria and pyelonephritis of pregnancy. Arch Intern Med 1960;105:194–8.
8. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). EUCAST Definitive Document E.DEF 3.1, June 2000: Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 2000; 6: 509–15.
9. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). EUCAST Definitive Document E.Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503–8.
10. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E.DEF 2.1, August 2000: Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 2000; 6: 570–2.
11. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard 4th Edition M7-A5 (2002) and M100-S12, 2004. Wayne, PA.
12. Rubin RH, Shapiro ED, Andriole VT et al. Evaluation of new anti-infective drugs for the treatment of UTI. Clin Infect Dis 1992; 15 (Suppl. 1): S216–27.
13. Rubin RH, Shapiro ED, Andriole VT et al., with modifications by a European Working Party (Norrby SR). General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993; 294–310.
14. Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents 1999; 11: 189-96; discussion 213–6.
15. Naber KG, Bergman B, Bjerklund-Johansen TE et al. Guidelines on urinary and male genital tract infections. European Association of Urology, 2001; latest edition 2004.
16. Naber KG, Bergman B, Bishop MC et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001; 40: 576–88.
17. Schneede P, Tenke P, Hofstetter AG. Members of the Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Sexually transmitted diseases (STDs) – a synoptic overview for urologists. Eur Urol 2003; 44: 1–7.
18. Cek M, Lenk S, Naber KG et al. Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol 2005; 48: 353–62.
19. Bichler K-H, Savatovsky I, Naber KG et al. EAU guidelines for the management of urogenital schistosomiasis. (Eur Urol in press).
20. Talan DA, Stamm WE, Hooton TM et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000; 283: 1583–90.
21. Talan DA, Klimberg IW, Nicolle LE et al. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004; 171: 734–9.
22. Naber KG, Schoenwald S, Hauke W. [Cefpodoxime proxetil in patients with acute uncomplicated pyelonephritis. International, prospective, randomized comparative study versus ciprofloxacin in general practice.] Chemotherapie ournal 2001; 10: 29–34.
23. Naber KG, Bartnicki A, Bischoff W et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004; 23 (Suppl. 1): 41–53.
24. Richard GA, Klimberg IN, Fowler CL et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52: 51–5.
25. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprimsulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987; 106: 341–5.
26. Bailey RR, Roberts AP, Gower PE, De Wardener HE. Prevention of urinary-tract infection with low-dose nitrofurantoin. Lancet 1971; 2: 1112–4.
27. Nunez U, Solis Z. Macrocrystalline nitrofurantoin versus norfloxacin as treatment and prophylaxis in uncomplicated recurrent urinary tract infection. Curr Therap Res Clin Exp 1990; 48: 234–45.
28. Brumfitt W, Cooper J, Hamilton-Miller JM. Prevention of recurrent urinary infections in women: a comparative trial between nitrofurantoin and methenamine hippurate. J Urol 1981; 126: 71–4.
29. Stamm WE, Wagner KF, Amsel R et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980; 303: 409–15.
30. Brumfitt W, Hamilton-Miller JM, Smith GW, al-Wali W. Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrodantin) in the prophylaxis of recurrent urinary tract infection in women. Q J Med 1991; 81: 811–20.
31. Seppanen J. Cinoxacin vs trimethoprim-safety and efficacy in the prophylaxis of uncomplicated urinary tract infections. Drugs Exp Clin Res 1988; 14: 669–71.
32. Melekos MD, Asbach HW, Gerharz E et al. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997; 157: 935–9.
33. Stamm WE, Counts GW, McKevitt M et al. Urinary prophylaxis with trimethoprim and trimethoprim-sulfamethoxazole: efficacy, influence on the natural history of recurrent bacteriuria, and cost control. Rev Infect Dis 1982; 4: 450–5.
34. Guibert J, Humbert G, Meyrier A et al. [Antibioprevention of recurrent cystitis.] A randomized double-blind comparative trial of 2 dosages of pefloxacin.] Presse Med 1995; 24: 213–6.
35. Gower PE. The use of small doses of cephalexin (125 mg) in the management of recurrent urinary tract infection in women. J Antimicrob Chemother 1975; 1 (Suppl. 3): 93–8.
36. Brumfitt W, Hamilton-Miller JM. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. Infection 1995; 23: 98–102.
37. Fraser IR, Birch D, Fairley KF et al. A prospective study of cortical scarring in acute febrile pyelonephritis in adults: clinical and bacteriological characteristics. Clin Nephrol 1995; 43: 159–64.
38. George NJ. Urinary tract infection. In: Mundy AR, George NJ, Fitzpatrick JM, Neill DE, eds. Scientific basis of urology. 2nd edition. ISIS Medical Media, 1998; p. 143–73.
39. Geerlings SE, Stolk RP, Camps MJ et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabet Care 2000; 23: 744–9.
40. Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the renal transplant recipient. In: Bergan T, ed. Urinary tract infections. Basel: Karger 1997; p. 27–33.
41. Rubin RH, Shapiro ED, Andriole VT et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1): 216–27.
42. Rubin RH, Shapiro ED, Andriole VT et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993; p. 240–310.
43. Kumazawa J, Matsumoto T. Complicated UTIs. In: Bergan T, ed. UTIs. Infectiology. Vol 1. Basel: Karger, 1997; p. 19–26.
44. Frankenschmidt A, Naber KG, Bischoff W, Kullmann K. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. J Urol 1997; 158: 1494–9.
45. Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997; 53: 583–92.
46. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21: 86–92.
47. Dobardzic AM, Dobardzic R. Epidemiological features of complicated UTI in a district hospital of Kuwait. Eur J Epidemiol 1997; 13: 465–70.
48. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11: 217–21.
49. Biering-Sorensen F. Urinary tract infection in individuals with spinal cord lesion. Curr Opin Urol 2002; 12: 45-9.
50. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int 2000; 86: 935–41.
51. Reid G. Biofilms in infectious diseases and on medical devices. Int J Antimicrob Agents 1999; 11: 223–6.
52. Habash M, Reid G. Microbial biofilms: their development and significance for medical device-related infections. J Clin Pharmacol 1999; 39: 887–98.
53. Goto T, Nakame Y, Nishida M, Ohi Y. In vitro bactericidal activities of beta-lactamases, amikacin and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology 1999; 53: 1058–62.
54. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387–92.
55. Kunin CM. Urinary tract infections: detection, prevention and management. 5th ed. Baltimore: Williams and Wilkins, 1997; p. 226–78.
56. Kumon H. Pathogenesis and management of bacterial biofilms in the urinary tract. J Infect Chemother 1996; 2: 18–28.
57.12. Cruse PJE, Foord R. The epidemiology of wound infection. A 10-year prospective of 62,939 wounds. Surg Clin North Am 1980; 60: 27–40.
58.5. Grabe M. Controversies in antibiotic prophylaxis in surgery. Int J Antimicrob Agents 2004; 23 (Suppl. 1): 17–23.
59.13. Love TA. Antibiotic prophylaxis and urologic surgery. Urology 1985; 26 (Suppl. 5): 2–5.
60.14. Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG; Working Group 'Urological Infections' of German Society of Urology. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Eur Urol 2005; 47: 549–56.
61.15. Grabe M, Forsgren A, Bjork T, Hellsten S. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol 1987; 6: 11–7.
62.16. Grabe M, Shortliffe L, Lobel B et al. Risk factors. In: Naber KG, Pechère JC, Kumazawa J et al., eds. Nosocomial and health care associated infections in urology. Health Publications Ltd, 2001; p. 35–57.
63.17. Adam D, Daschner F. Prevention of infection in surgery: hygienic measurements and antibiotic prophylaxis. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1993.
64.18. Blumenberg EA, Abrutyn E. Methods for reduction of UTI. Curr Opin Urol 1997; 7: 47–51.
65.19. Mignard JP for the Comité de Formation Continue, Association Francaise d'Urologie. Sterilisation and disinfection of instruments. Progrès en Urologie 2004; 14 (Suppl. 1): 1049–92.